|1st January 2021||Seymour Liebman||34,188||Exercise of derivative||$0.00|
|1st January 2021||David B Elsbree||34,188||Exercise of derivative||$0.00|
|4th December 2020||Sachs Group Inc Goldman||775,000||Bona fide gift||$0.00|
|30th November 2020||Sachs Group Inc Goldman||2,060,000||Bona fide gift||$0.00|
|13th November 2020||Sachs Group Inc Goldman||2,129,000||Bona fide gift||$0.00|
|12th November 2020||Sachs Group Inc Goldman||1,401,879||Other acquisition or disposition||$50.09||$70,220,119.11|
|28th September 2020||Sachs Group Inc Goldman||1,860||Exercise of in-the-money or at-the-money derivatives securities (usually options)||$0.00|
|22nd September 2020||Sachs Group Inc Goldman||1,013,165||Open or private sale||$19.00||$19,250,135.00|
|17th August 2020||Sachs Group Inc Goldman||1,500,000||Open or private sale||$27.50||$41,250,000.00|
|17th August 2020||Sachs Group Inc Goldman||225,000||Open or private sale||$27.50||$6,187,500.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
T2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology which enables rapid detection of pathogens, biomarkers and other abnormalities.